EphA2 as a Glioma-Associated Antigen: A Novel Target for Glioma Vaccines

This publication has 19 references indexed in Scilit:

• Expression of EphA2 is Prognostic of Disease-Free Interval and Overall Survival in Surgically Treated Patients with Renal Cell Carcinoma
  Clinical Cancer Research, 2005
• Vaccination with Tumor Lysate-Pulsed Dendritic Cells Elicits Antigen-Specific, Cytotoxic T-Cells in Patients with Malignant Glioma
  Cancer Research, 2004
• Malignant gliomas
  Current Neurology and Neuroscience Reports, 2004
• High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy
  Journal of Clinical Investigation, 2004
• Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo
  Oncogene, 2002
• Gene Therapy of Malignant Gliomas: A Pilot Study of Vaccination with Irradiated Autologous Glioma and Dendritic Cells Admixed with IL-4 Transduced Fibroblasts to Elicit an Immune Response
  Human Gene Therapy, 2001
• The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization
  Oncogene, 2000
• Immune selection after antigen-specific immunotherapy of melanoma
  Surgery, 1999
• HLA-A2.1–restricted Education and Cytolytic Activity of CD8+ T Lymphocytes from β2 Microglobulin (β2m) HLA-A2.1 Monochain Transgenic H-2Db β2m Double Knockout Mice
  The Journal of Experimental Medicine, 1997
• Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue
  Journal of Neurosurgery, 1981